1. Капранов Н.И., Каширская Н.Ю., ред. Муковисцидоз. М.: Медпрактика-М; 2014.
2. Fuchs H.J.H., Borowitz D.S., Christiansen D.H. et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozime Study Group. N. Engl. J. Med. 1994; 331 (10): 637-642. https://doi.org/10.1056/NEJM199409083311003.
3. Robinson M., Hemming A.L., Regnis J.A. et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax. 1997; 52 (10): 900-903. https://doi.org/10.1136/thx.52.10.900.
4. Eng P.A., Morton J., Douglass J.A. et al. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr. Pulmonol. 1996; 21 (2): 77-83. https://doi.org/10.1002/(SICI)1099-0496(199602)21:2<77::AID-PPUL3>3.0.CO;2-M.
5. Ballmann M., von der Hardt H. Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. J. Cyst. Fibros. 2002; 1 (1): 35-37.
6. Elkins M.R., Robinson M., Rose B.R. et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N. Engl. J. Med. 2006; 354 (3): 229-240. https://doi.org/10.1056/NEJMoa043900.
7. Cantor J.O., Shteyngart B., Cerreta J.M. et al. The effect of hyaluronan on elastic fiber injury in vitro and elastase-induced airspace enlargement in vivo. Proc. Soc. Exp. Biol. Med. 2000; 225 (1): 65-71.
8. Cantor J.O., Turino G.M. Can exogenously administered hyaluronan improve respiratory function in patients with pulmonary emphysema? Chest. 2004; 125 (1): 288-292. https://doi.org/10.1378/chest.125.1.288.
9. Scuri M., Abraham W.M. Hyaluronan blocks human neutrophil elastase (HNE)-induced airway responses in sheep. Pulm. Pharmacol. Ther. 2003; 16 (6): 335-340. https://doi.org/10.1016/S1094-5539(03)00089-0.
10. Buonpensiero P., De Gregorio F., Sepe A. et al. Hyaluronic acid improves "pleasantness" and tolerability of nebulized hypertonic saline in a cohort of patients with cystic fibrosis. Adv. Ther. 2010; 27 (11): 870-878. https://doi.org/10.1007/s12325-010-0076-8.
11. Ros M., Casciaro R., Lucca F. et al. Hyaluronic acid improves the tolerability of hypertonic saline in the chronic treatment of cystic fibrosis patients: a multicenter, randomized, controlled clinical trial. J. Aerosol. Med. Pulm. Drug Deliv. 2014; 27 (2): 133-137. https://doi.org/10.1089/jamp.2012.1034.
12. Симонова О.И., Горинова Ю.В. Новая форма гипертонического раствора для небулайзерной терапии. Вопросы современной педиатрии. 2016; 15 (6): 631-634. https://doi.org/10.15690/vsp.v15i6.1662.
13. Патрушева Ю.С., Бакрадзе М.Д. Этиология и факторы риска острого бронхиолита у детей. Вопросы диагностики в педиатрии. 2012; 4 (3): 45-52.
14. Симонова О.И., Горинова Ю.В., Бакрадзе М.Д. Эффективность ингаляций гипертонического раствора у детей с бронхитами и бронхиолитами. Вопросы современной педиатрии. 2014; 13 (4): 33-39. https://doi.org/10.15690/vsp.v13i4.1082.
15. Красовский С.А., Черняк А.В., Воронкова А.Ю. и др. (ред.). Регистр больных муковисцидозом в Российской Федерации. 2016 год. М.: Медпрактика-М; 2018.
16. Robinson M., Daviskas E., Eberl S. et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur. Respir. J. 1999; 14 (3): 678-685. https://doi.org/10.1034/j.1399-3003.1999.14c30.x.
17. Yaghi A., Zaman A., Dolovich M.B. The direct effect of hyperosmolar agents on ciliary beating of human bronchial epithelial cells. J. Aerosol. Med. Pulm. Drug Deliv. 2012; 25 (2): 88-95. https://doi.org/10.1089/jamp.2011.0914.
18. Bennett W.D., Henderson A.G., Donaldson S.H. Hydrator therapies for chronic bronchitis. lessons from cystic fibrosis. Ann. Am. Thorac. Soc. 2016; 13 (Suppl. 2): S186-190.
19. Aitken M.L., Bellon G., De Boeck K. et al. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am. J. Respir. Crit. Care Med. 2012; 185 (6): 645-652. https://doi.org/10.1164/rccm.201109-1666OC.
20. Nolan S.J., Thornton J., Murray C.S., Dwyer T. Inhaled mannitol (bronchitol) for cystic fibrosis. Paediatr. Respir. Rev. 2016; 18: 52-54. https://doi.org/10.1016/j.prrv.2015.12.001.
21. Middleton A., Robinson P.D., McKay K. et al. A pilot study of inhaled dry-powder mannitol during cystic fibrosis-related pulmonary exacerbation. Eur. Respir. J. 2015 45 (2): 541-544. https://doi.org/10.1183/09031936.00137814.
22. Amelina E., Flume P., Krasko V. et al. WS14.2. Phase 3 study of the efficacy and safety of inhaled mannitol in adults with cystic fibrosis. J. Cyst. Fibros. 2018; 17 (Suppl. 3): S25. https://doi.org/10.1016/s1569-1993(18)30197-8.
23. Чучалин А.Г., Айсанов З.Р., Чикина С.Ю. и др. Федеральные клинические рекомендации Российского респираторного общества по использованию метода спирометрии. Пульмонология. 2014; (6): 11-24. https://doi.org/10.18093/0869-0189-2014-0-6-11-24.
24. Daviskas E., Anderson S.D., Brannan J.D. et al. Inhalation of dry-powder mannitol increases mucociliary clearance. Eur. Respir. J. 1997; 10 (11): 2449-2454. https://doi.org/0.1183/09031936.97.10112449.
25. Daviskas E., Anderson S.D., Gomes K. et al. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum. Respirology. 2005; 10 (1): 46-56. https://doi.org/10.1111/j.1440-1843.2005.00659.x.
26. Goldman M.D., Daviskas E., Turton J.A. et al. Inhaled mannitol improves lung function assessed by forced oscillation in a placebo controlled trial in patients with bronchiectasis. Eur. Respir. J. 2004; 24: 470-471.